Golexanolone affords sustained improvement of Parkinson's symptoms in rats by reducing microglia activation that restores the glutamate-GABA-dopamine pathway.
- DOI
- 10.1016/j.neuropharm.2025.110759
- Published
- 2026 Feb 1
- Container
- Neuropharmacology
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.neuropharm.2025.110759,
title = {Golexanolone affords sustained improvement of Parkinson's symptoms in rats by reducing microglia activation that restores the glutamate-GABA-dopamine pathway.},
author = {Pedrosa MA and Mincheva G and Martinez-Garcia M and Vazquez L and Blackburn TP and Doverskog M and Llansola M and Felipo V},
year = {2026},
journal = {Neuropharmacology},
doi = {10.1016/j.neuropharm.2025.110759},
url = {https://doi.org/10.1016/j.neuropharm.2025.110759}
}RIS
TY - JOUR TI - Golexanolone affords sustained improvement of Parkinson's symptoms in rats by reducing microglia activation that restores the glutamate-GABA-dopamine pathway. AU - Pedrosa MA AU - Mincheva G AU - Martinez-Garcia M AU - Vazquez L AU - Blackburn TP AU - Doverskog M AU - Llansola M AU - Felipo V PY - 2026 JO - Neuropharmacology DO - 10.1016/j.neuropharm.2025.110759 UR - https://doi.org/10.1016/j.neuropharm.2025.110759 ER -
APA
MA, P., G, M., M, M., L, V., TP, B., M, D., M, L., & V, F. (2026). Golexanolone affords sustained improvement of Parkinson's symptoms in rats by reducing microglia activation that restores the glutamate-GABA-dopamine pathway.. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2025.110759
Source records
- pubmed · retrieved 2026-09-27T00:41:36.820Z
- europe-pmc · retrieved 2026-09-27T00:41:36.824Z